Floatz logo

Adriamycin

Ovarian Endometrioid Adenocarcinoma

National Cancer Institute (NCI)Small moleculePhase 3Active
BB
69/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
59/ 100
Competitive Position
89/ 100

Competitive context

40 Active assets in the Ovarian Endometrioid Adenocarcinoma cohort.

Asset / SponsorPhaseRating
Carboplatin
National Cancer Institute (NCI)
Phase 3BBB
Olaparib
University of Colorado, Denver
Phase 3BB
Cyclophosphamide
Roswell Park Cancer Institute
Phase 2BB
CIS-DIAMMINEDICHLOROPLATINUM II
Genelux Corporation
Phase 3BB
Pembrolizumab
Roswell Park Cancer Institute
Phase 2BB

View all 50 →

Same molecule, other indications

Adriamycin is also rated in:

adult acute lymphoblastic leukemiaActive
BBB
Indicative · Phase 4
77 / 100
View asset →
B-cell childhood acute lymphoblastic leukemiaDormant
BBB
Indicative · Phase 3
76 / 100
View asset →
hematopoietic and lymphoid system neoplasmActive
BBB
Indicative · Phase 4
76 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →